COVID-19 & Clinical Trials:
The Medidata Perspective

medidata

The COVID-19 pandemic has had a significant impact on clinical R&D. The decline in clinical trial enrollment reflects the current reality of the environment – and underscores the great potential of solutions developed by Medidata in the evolving landscape.

4 Critical Challenges to Solve

1 **Understanding the Evolving Situation**

2 **Reconsidering Trial Design to Enable Data Capture**

3 **Maintaining Quality and Supply**

4 **Accelerating Study Start Up**

Declining Trial Enrollment

April 2019

Average Decline in New Patients Entering Trials

April 2020

13+ International Authorities

have provided updated emergency guidance on trial conduct during the pandemic.

While regulations and guidance differ from country-to-country, there has been an overall **increase** in:

Promoting the use of technology in clinical trials



Pragmatism and flexibility

Virtualizing Clinical Trials

Remote approaches can mitigate delays in drug development related to the pandemic – and push clinical trials in a more patient-centric direction. [1]



trial sites are switching patients to virtual/ telemedicine

1 www.medidata.com/en/insight/covid-19-and-clinical-trials-the-medidata-perspective/#covid-survey

COVID-19 Clinical Trials
Are Using Medidata Technology

medidata

www.medidata.com/en/insight/covid-19-and-clinical-trials-the-medidata-perspective/